新型冠状病毒肺炎患者呼吸机相关性肺炎发生率增加:一项多中心队列研究
本研究为REA-REZO监测网络内的暴露/非暴露多中心队列研究,法国ICU中新型冠状病毒肺炎患者按年龄、性别、纳入中心、入院时抗菌治疗、患者来源、ICU入科至机械通气时间及入院时简化急性生理评分II与2016–2019年同一网络内患者1:1匹配。每组纳入1,879例。新型冠状病毒肺炎暴露组呼吸机相关性肺炎总体发生率更高(每1000通气日25.5,95%CI 23.7–27.45 vs 15.4,95%CI 13.7–17.3),首次和第二次呼吸机相关性肺炎累积发生率均更高(Gray检验P分别<0.0001和0.0167)。两组微生物生态与耐药模式相当,以肠杆菌目和非发酵革兰阴性菌为主,暴露组耐甲氧西林金黄色葡萄球菌比例更低(6% vs 23%;P=0.013)。
要点
- 新型冠状病毒肺炎暴露组呼吸机相关性肺炎总体发生率为每1000通气日25.5(95%CI 23.7–27.45),非暴露组为15.4(95%CI 13.7–17.3)。
- 首次呼吸机相关性肺炎累积发生率暴露组更高(Gray检验P<0.0001),第二次亦更高(Gray检验P=0.0167)。
- 两组微生物生态与耐药模式相当,以肠杆菌目和非发酵革兰阴性菌为主。
- 暴露组耐甲氧西林金黄色葡萄球菌比例低于非暴露组(6% vs 23%;P=0.013)。
- 研究未收集用药数据。
适用人群与场景
- 法国多中心ICU中入院时的新型冠状病毒肺炎患者,与2016–2019年同一REA-REZO监测网络内患者按年龄、性别、纳入中心、入院时抗菌治疗、患者来源、ICU入科至机械通气时间及入院时简化急性生理评分II进行1:1匹配。
研究设计与关键结果
- 研究设计为REA-REZO监测网络内的暴露/非暴露多中心队列研究,每组纳入1,879例。
- 呼吸机相关性肺炎总体发生率暴露组为每1000通气日25.5(95%CI 23.7–27.45),非暴露组为每1000通气日15.4(95%CI 13.7–17.3)。
- 首次呼吸机相关性肺炎累积发生率暴露组更高(Gray检验P<0.0001),第二次呼吸机相关性肺炎累积发生率暴露组更高(Gray检验P=0.0167)。
- 两组微生物生态与耐药模式相当,以肠杆菌目和非发酵革兰阴性菌为主。
- 暴露组耐甲氧西林金黄色葡萄球菌比例低于非暴露组(6% vs 23%;P=0.013)。
- 研究未收集用药数据。
证据类型、等级与局限
- 证据类型:多中心暴露/非暴露队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:新型冠状病毒肺炎患者呼吸机相关性肺炎发生率高于一般ICU人群,微生物生态与耐药模式相似。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Little is known about the epidemiology of ventilator-acquired pneumonia among coronavirus disease 2019 patients such as incidence or etiological agents. Some studies suggest a higher risk of ventilator-associated pneumonia in this specific population.
DESIGN: Cohort exposed/nonexposed study among the REA-REZO surveillance network.
SETTING: Multicentric; ICUs in France.
PATIENTS: The coronavirus disease 2019 patients at admission were matched on the age, sex, center of inclusion, presence of antimicrobial therapy at admission, patient provenance, time from ICU admission to mechanical ventilation, and Simplified Acute Physiology Score II at admission to the patients included between 2016 and 2019 within the same surveillance network (1:1).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The overall incidence of ventilator-associated pneumonia, the cumulative incidence, and hazard rate of the first and the second ventilator-associated pneumonia were estimated. In addition, the ventilator-associated pneumonia microbiological ecology and specific resistant pattern in coronavirus disease 2019 exposed and nonexposed patients were compared. Medication data were not collected. A total of 1,879 patients were included in each group. The overall incidence of ventilator-associated pneumonia was higher among coronavirus disease 2019 exposed patients (25.5; 95% CI [23.7-27.45] vs 15.4; 95% CI [13.7-17.3] ventilator-associated pneumonia per 1,000 ventilation days). The cumulative incidence was higher for the first and the second ventilator-associated pneumonia among the coronavirus disease 2019 exposed patients (respective Gray test p < 0.0001 and 0.0167). The microbiological ecology and resistance were comparable between groups with a predominance of Enterobacterales and nonfermenting Gram-negative bacteria. The documented resistance pattern was similar between groups, except for a lower rate of methicillin-resistant Staphylococcus aureus in the coronavirus disease 2019 exposed patient (6% vs 23%; p = 0.013).
CONCLUSIONS: There was a higher incidence of ventilator-associated pneumonia occurring among coronavirus disease 2019 patient compared with the general ICU population, with a similar microbiological ecology and resistance pattern.
参考来源
- Vacheron CH, Lepape A, Savey A, et al. Increased Incidence of Ventilator-Acquired Pneumonia in Coronavirus Disease 2019 Patients: A Multicentric Cohort Study. Crit Care Med. 2022. PMID: 34637422. doi:10.1097/CCM.0000000000005297
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。